Gilead: Remdesivir reduced risk of Covid death

Gilead Sciences said on Friday additional data from a latestage study showed its antiviral remdesivir reduced the risk of death and improved the conditions of severely ill Covid19 patients. The firm said the finding requires confirmation in clinical trials.